Gene Transfer into the Central and Peripheral Nervous System: Applications for the Treatment of Neurodegenerative Diseases and Peripheral Neuropathies

Biotechnology and Genetic Engineering Reviews

Volumn 20, Issue 1, 2003, Pages 49-76

  Pradat, Pierre François ^a   Mallet, Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEURODEGENERATIVE DISEASES;

CENTRAL NERVOUS SYSTEMS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; SYSTEM APPLICATIONS;

GENE TRANSFER;

ADENOVIRUS VECTOR; GENE PRODUCT; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR;

BACULOVIRUS; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; EX VIVO STUDY; GENE DELIVERY SYSTEM; GENE TARGETING; GENE TRANSFER; GENE VECTOR; HERPES SIMPLEX VIRUS; IN VIVO STUDY; MOTOR NEURON DISEASE; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; REVIEW; TRANSGENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; LENTIVIRUS; PARVOVIRUS; SIMPLEXVIRUS; UNIDENTIFIED BACULOVIRUS;

EID: 1242291891     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2003.10648037     Document Type: Article

References (238)

1. Acsadi, G., ANGUELOV, R.A., Y ANC, H, et al. (2002). Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Human Gene Therapy 13, 1047-1059.
2. AEBISCHBR, P. and Ridet, J. (2001). Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends in Neurosciences 24, 533-540.
3. AEBISCHBR, P., Winn, S.R., Tresco, P.A., Jaeger, C.B. and Greene, L.A. (1991). Transplantation of polymer encapsulated neuroiransmitter secreting cells: effect of the encapsulation technique. Journal of Biomedical Engineering 113, 178-183.
4. AEBISCHER, P., Pochon, N.A., Hiyd, B. et al. (1996a). Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenie cell line engineered to secrete hCNTF. Human Gene Therapy 1, 851-860.
5. AEBISCHER, P., SCHLUEP, M., DEGLON, N. et al (1996b). Intrathecal delivery of CNTFusing encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Medicine 2, 696-699.
6. Aihara, H. and Miyazaki, J. (1998). Gene transfer into muscle by electroporation in vivo. Nature Biotechnology 16, 867-870.
7. Akli, S., Caillaud, C., Vigne, E. et al. (1993). Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genetics, 3, 224-228.
8. Anwer, K., SHI, M., French, M.F. et al. (1998). Systemic effect of human growth hormone after intra-muscular injection of a single dose of a muscle-specific gene medicine. Human Gene Therapy 9, 659-670.
9. APPEL, S.C., SCHWARTZ, S., ADORNATO, B.T. et al. (2000). Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. JAMA 284, 2215-2221.
10. Azzouz, M., HOTTINGER, A., PATERNA, J.C., ZURN, A.D., AEBISCHER, P. and BUELER, H. (2000). Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intra-spinal injection of an adeno-associated virus encoding Bcl-2. Human Molecular Genetics 9, 803-811.
11. Bajocchi, G., Feldman, S.H., Crystal, R.G. and Mastrangeli, A. (1993). Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genetics 3, 229-234.
12. Balague, C., Kalla, M. and Zhang, W.W. (1997). Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. Journal of Virology 71, 3299-3306.
13. BANAL, S., JAKLITSCH, M.T., SHOU, M. et al. (1994). Angiogenic-induced enhancement of collateral blood flow to ischaemic myocardium by vascular endothelial growth factor in dogs. Circulation 89, 2183-2189.
14. BARKATS, M., NAKAO, N., GRASBON-FRODL, E.M. et al. (1997). Intra-striatal grafts of cmbryonic mescncephalic rat neurons genetically modified using an adenovirus encoding human Cu/Zn superoxide disimitase. Neuroscience 78, 703-713.
15. Barnett, F.H., Rainov, N.G., IKEDA, K. et al. (1999). Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Therapy 6, 14-20.
16. Bartlett, J.S., Samulski, R.J. and McCown, T.J. (1998). Selective and rapid uptake of adeno-associated virus type 2 in brain. Human Gene Therapy 9, 1181-1186.
17. BENCSICS, C., WACHTEL, S.R., MILSTIEN, S., HATAKEYAMA, K., BECKER, J.B. and KANG, U.I. (1996). Double transduction with GTP cyclohydrolase 1 and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. The Journal of Neuroscience 16, 4449-4456.
18. BENSIMON, G., LACOMBLEZ, L. and MEININGER, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New England Journal of Medicine 330, 585-591.
19. Bett, AJ., Haddara, W., Prevec, L. and Graham, F.L. (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proceedings of the National Academy of Sciences of the United States of America 91, 8802-8806.
20. Bickel, U., Yoshikawa, T. and Pardridge, W.M. (2001). Delivery of peptides and proteins through the blood-brain barrier. Advanced Drug Delivery Reviews 46, 247-279.
21. Bilang-Bleuel, A., Revah, F., Colin, P. et al. (1997). Intra-striatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the United Slates ofAmerica 94, 8818-8823.
22. BJORKLUND, A. and Lindvall, O. (2000). Cell replacement therapies for central nervous system disorders. Nature Neuroscience 3, 537-544.
23. BLOMER, U., NALDINI, L., KAFRI, T., TRONO, D., VERMA, I.M. and GAGE, F.H. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. Journal of Virology 71, 6641-6649.
24. BORDET, T., SCHMALBRUCH, H., Petttmann, B. et al. (1999). Adenoviral cardiotrophin-1 gene transfer protects pmm mice from progressive motor neuronopallly. Journal of Clinical Investigation 104, 1077-1085.
25. BORDET, T., LESBORDES, J.C., ROUHANI, S. et al. (2001). Protective effects of cardiotrophin-I adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice. Human Molecular Genetics 10, 1925-1933.
26. BOYCE, F.M. and BUCHER, N.L. (1996). Baculovirus-mediated gene transfer into mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 93, 2348-2352.
27. BROOKS, D.J. (1998). The early diagnosis of Parkinson’s disease. Annals of Neurology 44, S10-S18.
28. BROWN, R.H., Jr. and ROBBERECHT, W. (2001). Amyotrophic lateral sclerosis: pathogenesis. Seminars in Neurology 21, 131-139.
29. Brusca, J., Summers, M., Couch, J. and Courtney, L. (1986). Autographa culifomica nuclear polyhedrosis virus elficiently enters but does not replicate in poikilothermic vertebrate cells. Intervirology 26, 207-222.
30. Buc-Caron, M.H. (1995). Neuroepithelial progenitor cells explained from human fetal brain proliferate and differentiate in vitro. Neurobiology of Diseases 2, 37-47.
31. BUCHSCHACHER, G.L., Jr. and Wong-Staal, F. (2000). Development of lenti viral vectors for gene therapy for human diseases. Blood 95, 2499-2504.
32. CAMERON, N.E., COTTER, M.A. and LOW, P.A. (1991). Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. American Journal of Physiology 261, E1-E8.
33. Cao, L., Zheng, Z.C., Zhao, Y.C. et al. (1995). Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Human Gene Therapy 6, 1497-1501.
34. CHATTOPADHYAY, M., WOLFE, D., HUANG, S. et al. (2002). In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Annals of Neurology 51, 19-27.
35. Cuiu, A.Y., Zhai, P., Dal Canto, M.C. et al. (1995). Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences 6, 349-362.
36. CHOI-LUNDBERG, D.L., LIN, Q., CHANG, Y.N. et al. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841.
37. CLACKSON, T. (1997). Controlling mammalian gene expression with small molecules. Current Opinion in Chemical Biology 1, 210-218.
38. Cleveland, D.W. (1999). From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24, 515-520.
39. Conti, A.M., Fischer, SJ. and Windebank, A.J. (1997). Inhibition of axonal growth from sensory neurons by excess nerve growth factor. Annals of Neurology 42, 838-846.
40. Corbo, M. and Balmaceda, C. (2001). Peripheral neuropathy in cancer patients. Cancer Investigation 19, 369-382.
41. CORTI, O., Horellou, P., Colin, P., CATTANEO, E. and Mallet, J. (1996). Intra-cerebral teiracyelinc-dependent regulation of gene expression in grafts of neural precursors. Neuroreport 7, 1655-1659.
42. Corti, O., Sabate, O., Horellou, P. et al. (1999a). A single adenovirus vector mediates dox ycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nature Biotechnology 17, 349-354.
43. Corti, O., Sanchez-Capelo, a., Colin, P., Hanoun, N., Hamon, M. and Mallet, J. (1999b). Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 96, 12120-12125.
44. Costantini, L.C., Bakowska, J.C., Breakereld, X.O. and Isacson, O. (2000). Gene therapy in the CNS. Gene Therapy 7, 93-109.
45. CURTIS, R., ADRYAN, K.M., ZHU, Y., HARKNESS, P.J., LINDSAY, R.M. and DISTEFANO, P.S. (1993). Retrograde axonal transport of ciliary neurotrophic factor is increased by peripheral nerve injury. Nature 365, 253-255.
46. Danko, I. and Wolff, J.A. (1994). Direct gene transfer into muscle. Vaccine 12, 1499-1502.
47. Davidson, B.L., Allen, E.D., Kozarsky, K.F., Wilson, J.M. and Roessler, BJ. (1993). A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genetics 3, 219-223.
48. Davis, H.L., Demeneix, B.A., Quantin, B., Coulombe, J. and Whalen, R.G. (1993). Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Human Gene Therapy 4, 733-740.
49. Dedieu, J.F., Vigne, E., Torrent, C. et al. (1997). Long-term gene delivery into the livers of imimmocompetenl mice with E1/E4-defective adenoviruses. Journal of Virology 71, 4626-4637.
50. Distefano, P.S., Friedman, B., Radziejewski, C. et al. (1992). The neurotrophins BDNF. NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 8, 983-993.
51. Doran, S.E., REN, X.D., BETZ, A.L. et al. (1995). Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery 36, 965-970.
52. Draghia, R., Caillaud, C., Manicom, R., Pavirani, A., Kahn, A. and Poenaru, L. (1995). Gene delivery into the central nervous system by nasal instillation in rats. Gene Therapy 2, 418-423.
53. Driesse, M.J., KROS, J.M., Avezaat, C.J. et al. (1999). Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates. Human Gene Therapy 10, 2347-2354.
54. During, M.J., Naegele, J.R., O'Malley, K.L. and Geller, A.I. (1994). Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403.
55. During, M.J., Samulski, R.J., Elsworth, J.D. et al. (1998). In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-trealed monkeys using an AAV vector. Gene Therapy 5, 820-827.
56. DYCK, P.J. (1989). Hypoxic neuropathy: docs hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg lecture. Neurology 39, 111-118.
57. EAMES, R.A. and LANGE, L.S. (1967). Clinical and pathological study of ischaemic neuropathy. Journal of Neurology. Neurosurgety and Psychiatry 30, 215-226.
58. Engelhardt, J.F., Ye, X., Doranz, B. and Wilson, J.M. (1994). Ablation of E2A in recombinant adenoviruses improves transgcne persistence and decreases inflammatory response in mouse liver. Proceedings of the National Academy of Sciences of the United States of America 91, 6196-6200.
59. Fan, D.S., Ogawa, M., Fujimoto, K.I. et al. (1998). Behavioural recovery in 6-hydroxydopaminc-lesioncd rats by co-transduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated vims vectors. Human Gene Therapy 9, 2527-2535.
60. Farinon, A.M., Marbini, A., Gemignanl, F. et al. (1984). Skeletal muscle and peripheral nerve changes caused by chronic arterial insufficiency-signifieance and clinical correlations-histological, histochemical and ultrastructural study. Clinical Neuropathology 3, 240-252.
61. FEARNLUY, J.M. and LEES, A.J. (1991). Ageing and Parkinson's disease: substantianigra regional selectivity. Brain 114 (Pt. 5), 2283-2301.
62. FINIELS, F., Ribotta, M., Barkats, M. et al. (1995). Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neuron diseases. Neuroreport 7, 373-378.
63. Fink, D.J., DeLuca, N.A., Yamada, M., Wolke, D.P. and Glorioso, J.C. (2000). Design and application of HSV vectors for neuroprotection. Gene Therapy 7, 115-119.
64. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.J. and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
65. FISIIBR, L.J., JINNAH, H.A., KALE, L.C., HIGGINS, G.A. and GAGE, F.H. (1991). Survival and function of intra-striatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371-380.
66. Fitoussi, N., Sotnik-Barkai, I., Tornatore, C., Herzberg, U. and Yadid, G. (1998). Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes. Neuroscience 85, 405-413.
67. FRAEEKL, C., SONG, S., LIM, F. et al. (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. Journal of Virology 70, 7190-7197.
68. Freed, C.R., Breeze, R.E., Rosenberg, N.L. et al. (1992a). Survival of implanted fetal dopamine ceils and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New England Journal of Medicine 327, 1549-1555.
69. FREED, C.R., ROSENBERG, N.L., SCHNECK, S.A. and BREEZE, R.E. (1992b). Improved drug responsiveness following feial tissue implant for Parkinson's disease. Neurochemistry International, 20 Suppl 321S-327S.
70. FREED, C.R., GREENE, P.E., BREEZE, R.E. et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 344, 710-719.
71. FRIM, D.M., Uhler, T.A., GALPERN, W.R., BEAL, M.F., BREAKEFIELD, X.O. and ISACSON, O. (1994). Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent l-methyl-4-phenylpyridiniuni toxicity to dopaminergic neurons in the rat. Proceedings of the National Academy of Sciences of the United Suites of America 91, 5104-5108.
72. GAI, W.P., YUAN, H.X., Li, X.Q., POWER, J.T., Blumbergs, P.C. and JENSEN, P.H. (2000). In situ and in vitro study of co-localization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Experimental Neurology 166, 324-333.
73. GALPERN, W.R., Frim, D.M., TATTER, S.B., ALTAR, C. A., BEAL, M.F. and ISACSON, O. (1996). Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantianigra degeneration. Cell Transplantation 5, 225-232.
74. Ghadge, G.D., Roos, R.P., Kang, U.J. et al. (1995). CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Therapy 2, 132-137.
75. Glatzel, M., Flechsig, E., Navarro, B. et al. (2000). Adenoviral and adeno-associated viral transfer ol genes to the peripheral nervous system. Proceedings of the National Academy of Sciences of the United States of America 97, 442-447.
76. Goss, J.R., Mata, M., Goins, W.F., Wu, H.H., Glorjoso, J.C. and Fink, D.J. (2001). Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Therapy 8, 551-556.
77. Gossgn, M. and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proceedings of the National Academy of Sciences of the United States of America 89, 5547-5551.
78. GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W. and BUJARD, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.
79. GRAHAM, F.L. and PREVEC, L. (1995). Methods for construction of adenovirus vectors. Molecular Biotechnology 3, 207-220.
80. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C. and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. The Journal of General Virology 36, 59-74.
81. GRAVEL, C., GOTZ, R., LORRAIN, A. and SENDTNER, M. (1997). Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nature Medicine 3, 765-770.
82. GURNEY, M.E., Pu, H., Chiu, A.Y. et al. (1994). Motor neuron degeneration in mice that express a human Cu.Zn superoxide dismutase mutation. Science 264, 1772-1775.
83. Haase, G., Kennel, P., Pettmann, B. et al. (1997). Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nature Medicine 3, 429-436.
84. HAASE, G., PETTMANN, B., VIGNE, E., CASTELNAU-PTAKHINE, L., SCTIMALBRUCH, H. and KAHN, A. (1998). Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action. Journal of the Neurological Sciences, 160 Suppl, 1, S97-105.
85. Hadano, S., Hand, C.K., OSUGA, H. et al. (2001). A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genetics 29, 166-173.
86. Hagsirom, J.N., Couto, L.B., Scallan, C. et al. (2000). Improved muscle-derived expression of human coagulation factor IX from askcletal actin/CM V hybrid enhancer/promoter Blood 95, 2536-2542.
87. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y. and Phipps, M.L. (1997). Construction of adenovirus vectors through Crc-lox recombination. Journal of Virology 71, 1842-1849.
88. Harris, M., Eastman, R. and Cowie, C, (1993). Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care 16, 1446-1452.
89. Hartig, P.C., Cardon, M.C. and Kawanishi, C.Y. (1991). Insect virus: assays for viral replication and persistence in mammalian cells. Journal ofVirological Methods 31, 335-344.
90. HARVEY, D.M. and CASKEY, C.T. (1998). Inducible control of gene expression: prospects for gene therapy. Current Opinion in Chemical Biology 2, 512-518.
91. HERZOG, R.W., HAGSTROM, J.N., KUNG, S.H. et al. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intra-muscular injection of recombinant adeno-associated virus. Proceedings of the National Academy of Sciences of the United States of America 94, 5804-5809.
92. Hofmann, C., Sandig, V., Jennings, G., Rudolph, M., Schlag, P. and Strauss, M. (1995). Efficient gene transfer into human hepatocytes by baculovirtts vectors. Proceedings of the National Academy of Sciences of the United States of America 92, 10099-10103.
93. HORELLOU, P., Brundin, P., KALEN, P., MALLET, J. and BJORKLUND, A. (1990). In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervaled rat striatum. Neuron 5, 393-402.
94. HORELLOU, P., VIGNE, E., Castel, M.N. et al, (1994), Direct intra-cercbral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in arat model of Parkinsonsdisease. Neuroreport 6, 49-53.
95. Hsich, G., Sena-Esteves, M. and Breakereld, X.O. (2002). Critical issues in gene therapy for neurologic disease. Human Gene Therapy 13, 579-604.
96. HUGHES, R.A. (2002). Peripheral neuropathy. British Medical Journal 324,466-469.
97. Imaoka, T., Date, I., Ohmoto, T. and Nagatsu, T. (1998). Significant behavioral recovery in Parkinson's disease model by direct intra-cerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Human Gene Therapy 9, 1093-1102.
98. JIAO, S., WILLIAMS, P., BERG, R.K. et al. (1992). Direct gene transfer into nonhuman primate myofibers in vivo. Human Gene Therapy 3, 21-33.
99. Jin, B.K., Belloni, M., Conti, B. et al. (1996). Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Human Gene Therapy 7, 2015-2024.
100. Joung, I., Kim, H.S., Hong, J.S., Kwon, H. and Kwon, Y.K. (2000). Effective gene transfer into regenerating sciatic nerves by adenoviral vectors: potentials for gene therapy of peripheral nerve injury. Molecules and Cells 10, 540-545.
101. JULIEN, J.P. (2001). Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell 104, 581-591.
102. Kafri, T., Blomer, U., PETERSON, D.A., Gage, F.H, and Verma, I.M. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genetics 17, 314-317.
103. KANG, U J., FISHER, L.J., Joh, T.H., O’MALLEY, K.L. and GAGE, F.H. (1993). Regulation of dopamine production by genetically modified primary fibroblasts. The Journal of Neuro-science 13, 5203-5211.
104. KAPLITT, M.G., KWONG, A.D., KLEOPOULOS, S.P., Mobbs, C.V., RABKIN, S.D. and PFAFF, D.W. (1994a). Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proceedings of the National Academy of Sciences of the United States of America 91, 8979-8983.
105. KAPUTT, M.G., LEONE, P., SAMULSKI, R.J. et al. (1994b). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genetics 8, 148-154.
106. KECK, P.J., Hauser, S. D., KRIVI, G. et al. (1989). Vascular permeability actor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312.
107. Keir, S.D., Mitchell, W.J., Feldman, L.T. and Martin, J.R. (1995). Targeting and gene expression in spinal cord motor neurons following intra-muscular inoculation of an HS VI vector. Journal of Neurovirology 1, 259-267.
108. Kennedy, P.G. (1997). Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Brain 120 (Pi. 7). 1245-1259.
109. KHASAR, S.G., GOLD, M.S., DASTMALCHF, S. and LEVINE, J.D. (1996). Selective attenuation of mu-opioid receptor-mediated effects in rat sensory neurons by intrathecal administration of antisense oligodeoxynucleotides. Neuroscience Letters 218, 17-20.
110. Kirik, D., GEORGIESKA, B., Burger, C. et al. (2002). Reversal of motor impairments in parkinsonian rats by continuous intra-striatal delivery of L-dopa using rAAV-mediated gene transfer. Proceedings of the National Academy of Sciences of the United States of America 99, 4708-4713.
111. KITADA, T., Anakawa, S., Hattori, N. et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
112. Klein, R.L., Meyer, E.M., Peel, A.L. et al. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Experimental Neurology 150, 183-194.
113. Kochanek, S., Clemens, P.R., Mitani, K., CHEN, H.H., CHAN, S. and CASKEY, C.T. (1996), A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosida.se. Proceedings of the National Academy of Sciences of the United States of America 93, 5731-5736.
114. KOCHANEK, S., SCHIEDNER, G. and VOLPERS, C. (2001). High-capacity 'gutless' adenoviral vectors. Current Opinion in Molecular Therapeutics 3, 454-463.
115. KORDOWER, J.H., KMBORG, M.E., BLOCH, J. et al. (2000). Neurodegeneration prevented by lentiviral vector delivery ot’GDNF in primate models of Parkinson’s disease. Science 290, 767-773.
116. Kotin, R.M., LINDEN, R.M. and BERNS, K.I. (1992). Characterization of a preferred site on human chromosome I9q for integration of adeno-associated virus DNA by non-homo-logous recombination. The EMBO Journal 11, 5071-5078.
117. Kumar-Singh, R. and FARBER, D.B. (1998). Encapsidated adenovirus mini-chiomosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration. Human Molecular Genetics 7, 1893-1900.
118. Kurtzke, J.F. (1982). Epidemiology of amyotrophic lateral sclerosis. Advances in Neurology 36, 281-302.
119. Lacomblez, L., BENSIMON, G., Leigh, P.N., Guillet, P. and Meininger, V. (1996). Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/ Riluzole Study Group II. Lancet 347, 1425-1431.
120. LANG, A.L-. and LOZANO, A.M. (1998a). Parkinson’s disease. First of two parts. New England Journal of Medicine 339, 1044-1053.
121. LANG, A.E. and LOZANO, A.M. (1998b). Parkinson’s disease. Second of two parts. New England Journal of Medicine 339, 1130-1143.
122. LAPCHAK, P.A., ARAUJO, D.M., HILT, D.C., SHENG, J. and JIAO, S. (1997), Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Research 111, 153-160.
123. LATCHMAN, D.S. (2001). Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene 264, 1-9.
124. Lee, W.Y., CHANG, J.W., Nemeth, N.L. and KANG, U.J. (1999). Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3. 4-dihydroxyphenylalanine administration in parkinsonian rats. The Journal of Neuroscience 19, 3266-3274.
125. Leff, S.K., SPRATT, S.K., SNYDER, R.O. and MANDEL, R.J. (1999). Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 92, 185-196.
126. Le GaLLa Salle, G., Robert, J.J., Berrard, S. et al. (1993). An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259, 988-990.
127. Leroy, E., Boyer, R., Auburger, G. et al. (1998). The ubiquitin pathway in Parkinson’s disease. Nature 395, 451-452.
128. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. and Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitosien. Science 246, 1306-1309.
129. LEVIVIER, M., PRZEDBORSKI, S., BENCSICS, C. and KANG, U.J. (1995). Intra-striatal iniplan-union of fibroblasts genetically engineered to produce brain-derived neurotrophie factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. The Journal of Neuroscience 15, 7810-7820.
130. LEVY, M.Y., Barron, L.G., MEYER, K.B. and SZOKA, F.C., Jr. (1996). Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Therapy 3, 201-211.
131. LEWIS, P.F. and EMERMAN, M. (1994). Passage through mitosis is required for oncorelro viruses but not for the human immunodeficiency virus. Journal of Virology 68, 510-516.
132. Li, H., SUN, H. and Qian, Z.M. (2002). The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends in Pharmacological Sciences 23, 206-209.
133. Lieber, A., He, C.Y. and Kay, M.A. (1997). Adenoviral pre-icrminal protein stabilizes inini-adenoviral genomes in vitro and in vivo. Nature Biotechnology 15, 1383-1387.
134. LIMOUSIN, P., KRACK, P., POLLAK, P. et al. (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. New England Journal of Medicine 339, 1105-1111.
135. Lindner, M.D., Winn, S.R., Baetge, E.E. et al. (1995). Implantation of encapsulated catccholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Experimental Neurology 132, 62-76.
136. Lindvall, O., Widner, H., Rehncrona, S. et al., (1992). Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and ncurophysioiogical observations in two patients with putaminal implants. Annals of Neurology 31, 155-165.
137. LUNDBERG, C., HORELLOU, P., MALLET, J. and BJORKLUND, A. (1996). Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Experimental Neurology 139, 39-53.
138. MacCou, G.S., Goldspink, G. and Bouloux, P.M. (1999). Using skeletal muscle as an artificial endocrine tissue. Journal of Endocrinology 162, 1-9.
139. MacCou, G.S., Novo, F.J., Marshall, N.J., Waters, M., Goldspink, G. and Bouloux, P.M. (2000). Optimisation of growth hormone production by muscle cells using plasmid DNA. Journal of Endocrinology 165, 329-336.
140. Mandel, R.J., SPRATT, S.K., Snyder, R.O. and Leff, S.E. (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophie factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proceedings of the National Academy of Sciences of the United States of America 94, 14083-14088.
141. Mandel, R.J., Rendahl, K.G., Spratt, S.K., Snyder, R.O., Cohen, L.K. and Leff, S.E. (1998). Characterization of intra-striatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. The Journal of Neuroscience 18, 4271-4284.
142. Manthorpf, M., Cornefgrt-Jensisn, F., Hartikka, J. et al. (1993). Gene therapy by intra-muscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Human Gene Therapy 4, 419-431.
143. MARTYN, C.N. and HUGHES, R.A. (1997). Epidemiology of peripheral neuropathy. Journal of Neurology. Netirosttrgeiy and Psychiatry 62, 310-318.
144. McCown, TJ., Xiao, X., Li, J., BREESE, G.R. and SAMULSKI, R.J. (1996). Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Research 713, 99-107.
145. Millecamps, S., Kiefer, H.L., Navarro, V. et al. (1999). Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression. Nature Biotechnology 17, 865-869.
146. Miller, R.G., Petajan, J.H., Bryan, W.W. et al. (1996). A placebo-controlled trial of recombinant human ciliary neurotrophie (rhCNTF) factor in amyotrophic lateral sclerosis, rhCNTF ALS Study Group. Annals of Neurology 39, 256-260.
147. Mir, L.M., Bureau, M.F., Gehl, J. et al. (1999). High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proceedings of the National Academy of Sciences of the United States of America 96, 4262-4267.
148. MOGHAL, S., RAJPUT, A.H., D’arcy, C. and RAJPUT, R. (1994), Prevalence of movement disorders in elderly community residents. Nettroepidemiology 13, 175-178.
149. Mohajeri, M.H., FIGLEWICZ, D.A. and BOHN, M.C. (1999). Intra-musculargrafis of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent moto-neuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hitman Gene Therapy 10, 1853-1866.
150. MOLLMAN, J.E. (1990). Cisplatin neurotoxicity. New England Journal of Medicine 322, 126-127.
151. MORELU, A.E., Larrhgina, A.T., SMITH-ARICA, J. et al. (1999). Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. Journal of General Virology, 80 (Pt. 3), 571-583.
152. MORSY, M.A., Gu, M., MOTZET, S. et al. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leplin transgene. Proceedings of the National Academy of Sciences of the United States of America 95, 7866-7871.
153. Muldoon, L.L., Nilaver, G., Kroll, R.A. et al. (1995). Comparison of intra-cerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus. and iron oxide particles to normal rat brain. American Journal of Pathology 147, 1840-1851.
154. Muramatsu, S., Fujimoto, K., Ikeguchi, K. et al. (2002). Behavioral recovery in a primate model of Parkinson’s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Human Gene Therapy 13, 345-354.
155. MUZYCZKA, N. (1992). Use of adeno-associated vims as a general transduction vector for mammalian cells. Current Topics in Microbiology and Immunology 158, 97-129.
156. Naffakh, N., Pinset, C., Montarras, D, et al. (1996). Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Human Gene Therapy 7, 11-21.
157. Naldini, L., Blomhr, U., Gage, F.H., Trono, D. and Verma, I.M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America 93, 11382-11388.
158. Navarro, V., Millecamps, S., Geoffroy, M.C. et al. (1999). Efficient gene transfer and long-term expression in neurons using a recombinant adenovirus with a neuron-specific promoter. Gene Therapy 6, 1884-1892.
159. Nilaver, G., Muldoon, L.L., Kroll, R.A. et al. (1995). Delivery' of herpes virus and adenovirus to nude rat imra-cerebral tumors after osmotic blood-brain barrier disruption. Proceedings of the National Academy of Sciences of the United States of America 92, 9829-9833.
160. Norris, F., Shepherd, R., Denys, E. et al. (1993), Onset, natural history and outcome in idiopathic adult motor neuron disease. Journal of Neurological Sciences 118, 48-55.
161. OLSSON, Y. (1984). Vascular permeability in the peripheral nervous system. In: Peripheral neuropathy. Eds. P.J. Dyck, P.K. Thomas, E.H. Lambert and R.P. Bunge, pp 579-597. Philadelphia. USA: W.B. Saunders & Co.
162. PAKKENBERG, B., MOLLER, A., GUNDERSEN, H.J., MOURITZEN, D.A. and PAKKENBERG, H. (1991). The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereo logical method. Journal of Neurology. Neurosurgery and Psychiatry 54, 30-33.
163. PALMER, T.D., ROSMAN, G.J., OSBORNE, W.R. and MILLER, A.D. (1991). Genetically modified skin fibroblasts persist long alter transplantation but gradually inactivate introduced genes. Proceedings of the National Academy of Sciences of the United States of America 88, 1330-1334.
164. PASINI, F.L., Pastoreli, I.M., Beermann, U. et al. (1996). Peripheral neuropathy associated with ischaemic vascular disease of the lower limbs. Angiology 47, 569-577.
165. PEEL, A.L., ZOLOTUKHIN, S., SCHRIMSHER, G.W., MUZYCZKA, N. and REIER, PJ. (1997). Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Therapy 4, 16-24.
166. Piccini, P., LINDVALL, O., BJORKLUND, A. et al. (2000). Delayed recovery of movement-rclatcd cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 48, 689-695.
167. PIERONI, L. and LA Monica, N. (2001). Towards the use of baculovirus as a gene therapy vector. Current Opinion in Molecular Therapeutics 3. 464-467.
168. Pirart, J. (1978). Why don't we teach and treat diabetic patients better? Diabetes Care 1.139-140.
169. Polymeropoulos, M.H., Lavedan, C., Leroy, E. et al. (1997). Mutation ill the alpha-synuclcin gene identified in families with Parkinson’s disease. Science 276, 2045-2047.
170. Pradat, P.F., Finiels, F., Kennel, P. et al. (2001a). Partial prevention of cisplatin-induced neuropathy by electroporation-mediated non-viral gene transfer. Human Gene Therapy 12, 367-375.
171. Pradat, P.F., Kennel, P., Naimi-Sadaoui, S. et al. (2000b). Continuous delivery of ncurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylainidc neuropathies. Human Gene Therapy 12, 2237-2249.
172. Pradat, P.F., Kennel, P., Naimi-Sadaoui, S. et al. (2002). Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy. Gene Therapy 9, 1333-1337.
173. Rainov, N.G., ZIMMER, C., Chase, M. et al. (1995). Selective uptake of viral and monocrystalline particles delivered intra-artcrially to experimental brain neoplasms. Human Gene Therapy 6, 1543-1552.
174. Rainov, N.G., Dobberstein, K.U., Heidecke, V. et al. (1998). Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Therapy 5, 158-162.
175. Raz, E., Watanabe, A., Baird, S.M. et al. (1993). Systemic immunological effects of cytokine genes injected into skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America 90, 4523-4527.
176. Ridet, J.L., Corti, O., Pencalgt, P. et al. (1999). Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes. Human Gene Therapy 10, 271-280.
177. RIDOUX, V., ROBERT, J.J., ZHANG, X., PERRICAUDET, M., MALLE T. J. and LE GAL, L.S. (1994). The use of adenovirus vectors for intra-cerebral grafting of transfected nervous cells. Neuroreport 5, 801-804.
178. ROB, T., REYNOLDS, T.C., YU, G. and BROWN, P.O. (1993). Integration of murine leukemia virus DNA depends on mitosis. EMBO Journal 12, 2099-2108.
179. ROELOFS, R.I., HRUSHESKY, W., ROGIN, J. and ROSENBERG, L. (1984). Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34, 934-938.
180. Rosen, D.R., Siddique, T., Patterson, D. et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
181. ROWLAND, L.P. and SHNEIDER, N.A. (2001). Amyotrophic lateral sclerosis. New England Journal of Medicine 344, 1688-1700.
182. SABATE, O., HORELLOU, P., VIGNE, E. et al. (1995). Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses. Nature Genetics 9, 256-260.
183. Saeki, Y., Ichikawa, T., Saeki, A. et al. (1998). Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Human Gene Therapy 9, 2787-2794.
184. Sagot, Y., Tan, S.A., Baetge, E., Schmalbruch, H., Kato, A.C. and Aebischer, P. (1995). Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophie factor can slow down progressive motor neuronopathy in the mouse. European Journal of Neurosciences 7, 1313-1322.
185. SAHENK, Z., SEHARASEYON, J., MENDELL, J.R. and BURGHES, A.H. (1993). Gene delivery to spinal motor neurons. Brain Research 606, 126-129.
186. SAID, G. (1996). Diabetic neuropathy: an update. Journal of Neurology 243, 431-440.
187. Sarkis, C., Serguera, C., Petres, S. et al. (2000). Efficient transduction of neural cells in vitro and in vivo by a bacuiovirus-derived vector. Proceedings of the National Academy of Sciences of the United States of America 97, 14638-14643.
188. Sautter, J., TSENG, J.L., BRAGUGLIA, D. et al. (1998). Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Experimental Neurology 149, 230-236.
189. SCHMALBRUCH, H., JENSEN, H.J., BJAERG, M., KAMIENIECKA, Z. and KURLAND, L, (1991). A new mouse mutant with progressive motor neuronopathy. Journal of Neuropathology and Experimental Neurology 50, 192-204.
190. Schraizberglir, P., Walter, D.H., Rittig, K. et al. (2001). Reversal of experimental diabetic neuropathy by VEGF gene transfer. Journal of Clinical Investigation 107, 1083-1092.
191. SEGOVIA, J., VERGARA, P. and BRENNER, M. (1998). Astrocyte-specific expression of tyrosine hydroxylase after intra-cerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Therapy 5, 1650-1655.
192. Sendtner, M (1997). Gene therapy for motor neuron disease. Nature Medicine 3, 380-381.
193. SENGHR, D.R., GALLI, S.J., DVORAK, A.M., PERRUZZJ, C.A., HARVEY, V.S. and DVORAK, H.F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
194. SEPPEN, J., BARRY, S.C., HARDER, B. and OSBORNE, W.R. (2001). Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 98, 594-596.
195. SHI, N. and PARDRIDGE, W.M. (2000). Noninvasive gene targeting to the brain. Proceedings of the National Academy of Sciences of the United States of America 97, 7567-7572.
196. Shi, N., Zhang, Y., Zhu, C., Boado, R.J. and Pardridge, W.M. (2001), Brain-specific expression of an exogenous gene after i.v, administration. Proceedings of the National Academy of Sciences of the United States of America 98, 12754-12759.
197. SIMOVIC, D., ISNER, J.M., ROPPER, A.H., PIECZEK, A. and WEINBERG, D.H. (2001). Improve-ment in chronic ischaemic neuropathy after imra-muscular phVEGF 165 gene transfer in patients with critical limb ischaemia. Archives of Neurology 58, 761-768.
198. Snyder, R.O., Sprall, S.K., Lagarde, C. et al. (1997). ElIicient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Human Gene Therapy 8, 1891-1900.
199. SPAETE, R.R. and FRENKEL, N. (1982). The herpes simplex virus amplicon: a new eukaryotic defective-virus cloning-amplifying vector. Cell 30, 295-304.
200. SPENCER, D.D., Robbins, R.J., Naitolin, F. et al. (1992). Unilateral transplantation of human ¡etal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. New England Journal of Medicine 327, 1541-1548.
201. STANDIFKR, K.M., JENAB, S., Su, W. et al. (1995). Antisense oligodeoxynucleotides to the cloned delta receptor DOR-1: uptake, stability, and regulation of gene expression. Journal of Neurochemistry 65, 1981-1987.
202. SIAVROPOULOS, I.A. and STRATHDEE, C.A. (1998). An enhanced packaging system for helper-dependent herpes simplex virus vectors. Journal of Virology 72, 7137-7143.
203. STEVENS, E.J., CARRINGTON, A.L. and TOMLINSON, D.R. (1994). Nerve ischaemia in diabetic rats: lime-course of development, el led of insulin treatment plus comparison of strepto/.otoein and BB models, Diahetologia 37, 43-48.
204. Tan, S.A., Deglon, N., Zukn, A.D. et al. (1996). Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell Transplantation 5, 577-587.
205. TAYLOR, J.P., HARDY, J, AND FISCHBECK, K.H. (2002). Toxic proteins in neurodegenerative disease. Science 296, 1991-1995.
206. Tesiaye, S., Harris, N., Jakubowski, J.J. et al. (1993). Impaired blood flow and arteriovenous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diahetologia 36, 1266-1274.
207. Tesfaye, S., Stevens, L.K., Stephenson, J.M. et al. (1996). Prevalence of diabetic peripheral neuropathy and its relation toglycaemic control and potential risk factors: the EURODIAB iDDM Complications Sludy. Diabetologia 39, 1377-1384.
208. THOMAS, P.K. and Tomlinson, D.R. (1993). Diabetic and hypoglycemic neuropathy, in: Peripheral neuropathy. Eds. P.J. Dyck and P.K. Thomas, pp. 1219-1250. Philadelphia. USA: W.B. Saunders.
209. Thompson, S.W., Davis, L.E., Korneeld, M., Hilgers, R.D. and Standefer, J.C. (1984). Cisplatin neuropathy. Clinical, electrophysiologic. morphologic, and toxicologic studies. Cancer 54, 1269-1275.
210. Thorne, R.G. and Frey, W.H. (2001). Delivery of neurotrophie factors to the central nervous system: pharmacokinetic considerations. Clinical Pharmacokinetics 40, 907-946.
211. Trejo, F., Vergara, P., Brenner, M. and Segovia, J. (1999). Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sciences 65, 483-491.
212. Tripathy, S.K., Goldvvasser, E., Lu, M.M., Barr, E. and Leiden, J.M. (1994). Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intra-niuscular injection of replication-defective adenovirus. Proceedings of the National Academy of Sciences of the United States of America 91, 11557-11561.
213. Tripathy, S.K., Svensson, E.C., Black, H.B. et al. (1996). Long-term expression of erythropoietin in the systemic circulation of mice after intra-muscular injection of a plasmid DNA vector. Proceedings of the National Academy of Sciences of the United States of America 93, 10876-10880.
214. Trono, D. (2000). Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Therapy 7, 20-23.
215. Tuck, R.R., Schmelzer, J.D. and Low, P.A. (1984). Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107 (Pt. 3), 935-950.
216. van der Hoop, R.G., van der Burg, M.E., Bokkel Huinink, W.W., van Houwelingun, C. and Neijt, J.P. (1990). Incidence of neuropathy in 395 patients with ovarian cancer treated wiih or without cisplatin. Cancer 66, 1697-1702.
217. Vandenburch, J-J., Dei Tatto, M., Shansky, J. et al. (1996). Tissue-engineered skeletal muscle organoids for reversible gene iherapy. Human Gene Therapy 7, 2195-2200.
218. Wahlestedt, C., Pich, E.M., Koob, G.F., Yee, F. and Heilig, M. (1993). Modulation of anxiety and neuropeptide Y-YI receptors by antisense oligodeoxvnucleotides. Scicnce 259, 528-531.
219. Walker, S.L., Wonderling, R.S. and Owens, R. A. (1997). Mutational analysis of the adeno-associated virus Rep68 protein: identification of critical residues necessary for site-specific endonuclease activity. Journal of Virology 71, 2722-2730.
220. WANG, Q. and Finer, M.H. (1996). Second-generation adenovirus vectors. Nature Medicine 2, 714-716.
221. Wang, Q., Greenburg, G., Bunch, D., Farson, D. and Finer, M.H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a delta HI/della E4 adenovirus vector. Gene Therapy 4, 393-400.
222. WEITZMAN, M.D., Kyostio, S.R., Kotin, R.M. and Owens, R.A. (1994). Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proceedings of the National Academy of Sciences of the United States of America 91, 5808-5812.
223. Wolff, J.A., Malone, R.W., Williams, P. et al. (1990). Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468.
224. Wolff, J. A., Dowty, M.E., Jiao, S. et al., (1992). Expression of naked plasmids by cultured myotubcs and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. Journal of Cell Science 103, 1249-1259.
225. WOLOZIN, B. and Behl, C. (2000). Mechanisms of neurodegeneralive disorders: Part 1: protein aggregates. Archives of Neurology 57, 793-796.
226. Wood, M.I., Charlton, H.M., Wood, K.J., Kajiwara, K. and Byrnes, A.P. (1996). Immune responses to adenovirus vectors in the nervous system. Trends in Neitrosciences 19, 497-501.
227. Wu, P., PHILLIPS, M.I., Bui, J. and TERWILLIGER, E.F. (1998), Adeno-associated virus vector-mediated transgene integration into neurons and other non-dividing cell targets. Journal of Virology 72, 5919-5926.
228. Xiao, X., Li, J. and Samulski, R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. Jownul of Virolotiv 72, 2224-2232.
229. YAMADA, M., OLIGINO, T., MATA, M., GOSS, J.R., GLORIOSO, J.C. and FINK, D.J. (1999). Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydmxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proceedings of the National Academy of Sciences of the United States of America 96, 4078-4083.
230. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol, E. and Wilson, J.M. (1994a). Cellular immunity to viral antigens limits Ei-deleted adenoviruses for gene therapy. Proceedings of the National Academ v of Sciences of the United States of America 91, 4407-4411.
231. Yang, Y., Nunes, F.A., Berencsi, K., Gonczol, E., Engelhardt, J.F. and Wilson, J.M. (1994b). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 7, 362-369.
232. Yao, S.N., Smith, K.J. and Kurachi, K. (1994). Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Therapy, 1, 99-107.
233. YEE, F., ERICSON, H., Reis, D.J. and Wahlestedt, C. (1994). Cellular uptake of intracerebroventricularly administered biotin-or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. Cellular and Molecular Neurobiology 14, 475-486.
234. YOSHIMOTO, Y., LIN, Q., COLLIER, T.J., FRIM, D.M., BREAKEFIELD, X.O. and BOHN, M.C. (1995). Astrocytes retrovirally transduced with BDNFelicit behavioral improvement in a rat model of Parkinson’s disease. Brain Research 691, 25-36.
235. Young, M.J., Boulton, A.J., MacLeod, A.F., Williams, D.R. and Sonksen, P.H. (1993). A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diahetologia 36, 150-154.
236. Zhang, Z.X. and Roman, G.C. (1993). Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology 12, 195-208.
237. Zolotukhin, S., Byrne, B.J., Mason, E. et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 6.973-985.
238. ZURN, A.D., HENRY, H., SCHLUEP, M. et al. (2000). Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplantation 9, 471-484.